No Data
AUSTAR: 2024 Annual Report
AUSTAR (06118.HK): Recorded revenue of 1.5 billion yuan in the 2024 fiscal year, a year-on-year decrease of 14.9%.
On March 26, Gelonghui reported that AUSTAR (06118.HK) announced that for the fiscal year ending December 31, 2024, the group recorded revenue of approximately RMB 1.5004 billion, a decrease of 14.9% compared to the same period in 2023, mainly due to a significant drop of about 32.7% in the order volume throughout 2023, resulting in a decrease in uncompleted contracts at the beginning of the period. However, compared to the losses recorded in 2023, the after-tax Net income for 2024 shows a turnaround to profit, with the order intake for 2024 increasing by 12.1% compared to the same period in 2023. This turnaround to profit is attributed to management.
Express News | Austar Lifesciences FY Revenue RMB 1,500.4 Million
AUSTAR: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024
Austar Lifesciences to Review Annual Results and Dividend Proposal
AUSTAR (06118.HK) plans to hold a Board of Directors meeting on March 26 to approve the annual performance.
Gelonghui, March 14th丨AUSTAR (06118.HK) announced that the Board of Directors meeting will be held on March 26, 2025 (Wednesday), to consider and approve the annual performance of the group for the year ending December 31, 2024, and the proposed final dividend distribution (if any).
Investors Give Austar Lifesciences Limited (HKG:6118) Shares A 27% Hiding
